Leukotriene-receptor antagonists

Lancet

Volumn 353, Issue 9146, 1999, Pages 57-62

  Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CYCLOSPORIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; TERFENADINE; ZAFIRLUKAST;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALLERGIC RHINITIS; ASTHMA; CHEMICAL STRUCTURE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DEVELOPMENT; DRUG EFFICACY; DYSPEPSIA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0033513988     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)09019-9     Document Type: Review

References (49)

1. National Asthma Education and Prevention Programme. Expert panel report II:. guidelines for the diagnosis and management of asthma. Bethesda: National Institutes of Health Publication, 1997; 97-27.
2. Lipworth B.J. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol. 9:1996;19-27.
3. Hay D.W.P. Pharmacology of leukotriene receptor antagonists: more than inhibiters of bronchoconstriction. Chest. 111:1997;35S-45S.
4. Dahlen S.E., Hedqvist P., Hammarsterom S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 288:1980;484-486.
5. O'Byrne P.M. Leukotrienes in the pathogenesis of asthma. Chest. 111:1997;27S-34S.
6. Cheng H., Leff J.A., Main Ret al. Pharmacokinetics, bioavailability and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res. 13:1996;445-448.
7. Zhao J.J., Rogers J.D., Holland SDet al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos. 80:1997;769-777.
8. Adkins J.C., Brogden R.N. Zafirlukast: a review of its pharmacology and therapeutic potential in the management of asthma. Drugs. 55:1998;121-144.
9. Chiba M., Xu X., Nishime J.A., Balani S.K., Lin J.H. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist in humans. Drug Metab Dispos. 26:1997;1022-1031.
10. Taylor I.K., O'Shaughnessy K.M., Fuller R.W., Dollary C.T. Effective cysteinyl leukotriene receptor antagonists ICI 204219 on allergen induced bronchoconstriction in airway hyperreactivity in atopic subjects. Lancet. 337:1991;690-694.
11. Hamilton A., Faiferman I., Stober P., Watson M., O'Byrne P.M. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early and late phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol. 102:1998;177-183.
12. Roquet A., Dahlen B., Kumlin Met al. Combined antagonism of leukotrienes and histamine produces predominate inhibition of allergen induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med. 155:1997;1856-1863.
13. Calhoun W.J., Lavins B., Minkwitz M.C., Evans R., Gleich G., Cohn J. Effect of zafirlukcast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med. 157:1998;138-139.
14. Leff J.A., Pizzichini E., Efthimiadis Aet al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly controlled asthma: a randomised placebo control trial. Am J Respir Crit Care Med. 155:1997;A977.
15. Rosenthal R., Lavins B.J., Hanby L.A. Effect of treatment with zafirlukast (Accolate) on bronchial hyperresponsiveness in patients with mild to moderate asthma. J Allergy Clin Immunol. 97(part 3):1996;250.
16. Westbroek J., Pasma H.R. The effect of inhaled fluticasone propionate 100 μg bd compared with oral zafirlukast 20 mg bd on bronchial hyperresponsiveness in mild to moderate asthmatic. Eur Respir J. 19(suppl 25):1997;248S.
17. Nakamura Y., Hoshino M., Sim J.J., Ishii K., Hosaka K., Sakamoto T. Effect of the leukotriene-antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax. S3:1998;835-841.
18. Spector S.L., Smith L.J., Glass M. Effects of 6 weeks of therapy with oral doses of ICI204, 219, a leukotriene D4 receptor antagonist in subjects with bronchial asthma. Am J Respir Crit Care Med. 150:1994;618-623.
19. Noonan M.J., Chervinsky P., Brandon Met al. Montelukast a potent leukotriene receptor antagonist causes dose related improvements in chronic asthma. Eur Respir J. 11:1998;1232-1339.
20. Altman L.C., Munk Z., Seltzer Jet al. A placebo-controlled dose-ranging study of montelukast a cysteinyl leukotriene receptor antagonist. J Allergy Clin Immunol. 102:1998;50-56.
21. Knorr B., Matz J., Bernstein JAet al. Montelukast for chronic asthma in 6 to 14 year old children. JAMA. 279:1998;1181-1186.
22. Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., Edwards T.B. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: a multicentre, randomized double-blind trial. Arch Intern Med. 158:1998;1213-1220.
23. Fish J.E., Kemp J.P., Lockey R.F., Glass M., Hanby A.A., Bonuccelli C.M. Zafirlukast for symptomatic mild to moderate asthma, a 13 week multicentre study. Clin Ther. 19:1997;675-690.
24. Suissa S., Dennis R., Ernst P., Sheehy O., Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild to moderate asthma: a randomized, double-blind, placebo control trial. Ann Intern Med. 126:1997;177-183.
25. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, September, 1998, no 36.
26. Laitinen L.A., Nayai P., Binks S., Harris A. Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prn β2-agonists. Eur Respir J. 10(suppl 25):1997;419S-420S.
27. Malmstrom K., Guerra J., Redriguez-Gomez Get al. A comparison of montelukast, a leukotriene receptor antagonist and inhaled beclomethasone in chronic asthma. Eur Respir J. 12(suppl 28):1998;36S.
28. Ringdal N., Whitney J.G., Summerton L. A comparison of patient preference for treatment with oral zafirlukast or inhaled beclomethasone. Eur Respir J. 10(suppl 25):1997;437S.
29. Barnes N.C., Black B., Syerett N., Cohns J. Reduction of exacerbations of asthma in multinational clinical trials with zafirlukast (Accolate). Am J Respir Crit Care Med. 143(part 2):1996;A802.
30. Cowburn A.S., Sladek K., Soja Ret al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin intolerant asthma. J Clin Invest. 101:1998;834-846.
31. Christie P.E., Smith C.M., Lee T.H. The potent and selective sulfidopeptide leukotriene antagonist, SK and F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis. 144:1991;957-958.
32. Dahlen B.M., Kumlin D.J., Margolskee Cet al. The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine aspirin in aspirin-sensitive asthmatics. Eur Respir J. 6:1993;1018-1026.
33. Leff J.A., Busse W.W., Pullman Det al. Montelukast, a leukotriene receptor antagonist for the treatment of mild asthma and exercise induced bronchoconstriction. N Engl J Med. 339:1998;147-152.
34. Kemp J.P., Dockhorn R.J., Shapiro GGet al. Montelukast once daily inhibits exercise induced bronchoconstriction in 6 to 14 year old children with asthma. J Paediatr. 133:1998;424-428.
35. Hofstra W.B., Sterk P.J., Neijens H.J., Van der Weij A.M., Van Zouest J.C.M., Duiverman E.J. Short-term treatment with zafirlukast, sodium cromoglycate or placebo in reducing exercise induced bronchoconstriction in adolescent asthmatics. Eur Respir J. 10(suppl 25):1997;220S.
36. Turpin J.A., Edelman J.M., De Lucca P.T., Pearlman D.S. Chronic administration of montelukast is superior to inhaled salmeterol in the prevention of exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 157(part 2):1998;A456.
37. Pauwels R., Lofdahl C.G., Postma Det al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 337:1997;1405-1411.
38. Nayak A.S., Anderson P., Charous B.L., Williams K., Simonson S. Equivalence of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients symptomatic on low-dose inhaled corticosteroids. J Allergy Clin Immunol. 101(part 2):1998;S233.
39. Leff J.A., Israel E., Noonan NJet al. Montelukast allows tapering of inhaled corticosteroids in asthmatic patients whilst maintaining clinical stability. Am J Respir Crit Care Med. 155(part 2):1997;A976.
40. O'Shaughnessy K.M., Wellings R., Gillies B., Fuller R.W. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary lukotriene E4 excretion. Am Rev Respir Dis. 147:1993;142-146.
41. Dworski R., Fitzgerald G.A., Oats J.A., Sheller J.R., Workman R., Prakash C. Effect of oral prednisolone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med. 149:1994;953-959.
42. Riddick C.A., Ring L.L., Baker J.R., Hodulik R., Bigby T.D. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in humna monocytes and THP-1 cells. Eur J Biochem. 246:1997;112-118.
43. In K.H., Asano K., Beier Det al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 99:1997;1130-1137.
44. Wechsler M.E., Garbpestad E., Flier SRet al. Pulmonary infiltrates, eosinophilia and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 279:1998;455-457.
45. Naclerio R.M., Baroody F.M., Togias A.G. The role of leukotrienes in allergic rhinitis, a review. Am Rev Respir Dis. 143:1991;S91-S95.
46. Knapp H.R. Reduced allergen induced nasal symptoms and leukotrienes synthesis with an orally active 5-lipoxygenase inhibiter. N Engl J Med. 323:1990;1745-1748.
47. Grossman J., Ratner P.H., Nathen R., Adelglass J., De Joung B. Pranlukast (ultair, SB205312, ONO1078), an oral leukotriene receptor antagonist relieve symptoms in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 99(part 2):1997;S443.
48. Donnelly A.R., Glass M., Minkwitz M.C., Casale T.M. The leukotriene D4 receptor antagonists, ICI204219, relieve symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 151:1995;1734-1739.
49. Malmstrom K., Meltzer E., Prenner Bet al. Effects of montelukast (a leukotriene receptor antagonist), Loratidine, montelukast plus loratidine and placebo in seasonal allergic rhinitis and conjunctivitis. J Allergy Clin Immunol. 101(part 2):1998;S97.